Time course of histological progression in primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would be helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo- controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41%, 43%, and 35% of the patients, and after 2 years in 62%, 62%, and 50% of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31% and 50% of the patients in stage I and stage II at entry, respectively. A minority (20%) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2%). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median time to develop extensive fibrosis (≥F3) was 2 years.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [53]
In the citing paper
“The median time to develop extensive fibrosis (≥F3) was 2 years.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [54]
In the citing paper
“Several randomized trials, combined analyses, and long-term observational studies have shown that UDCA not only improves biochemical indices but also delays histologic progression and improves survival without transplantation.(53,(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [53]
Citations
Cites
The Jackknife, the Bootstrap and Other Resampling Plans
Efron, B. (1982) · Society for Industrial and Applied Mathematics eBooks · doi:10.1137/1.9781611970319 · Cited by 8,120
Statistical Models Based on Counting Processes
Bry, X., Andersen, P. K., Borgan, Ø., Gill, R. D., Keiding, N., & Borgan, O. (1997) · Population (French Edition) · doi:10.2307/1534625 · Cited by 2,884
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Nineteen Dubious Ways to Compute the Exponential of a Matrix
Moler, C., & Van Loan, C. (1978) · SIAM Review · doi:10.1137/1020098 · Cited by 1,526
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Self-citationElements of the theory of Markov processes and their applications
(1960) · Journal of the Franklin Institute · doi:10.1016/0016-0032(60)90686-4 · Cited by 731
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citation
Cited by
Items 101–185 of 185
Sayıner, M., Stepanova, M., de Avila, L., Golabi, P., Racila, A., & Younossi, Z. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05786-1 · Cited by 14
Mawardi, M., Alalwan, A. M., Fallatah, H. I., Abaalkhail, F. A., Hasosah, M. Y., Shagrani, M. A., Alghamdi, M., & Alghamdi, A. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_112_21 · Cited by 14
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis
Burman, B. E., Jhaveri, M. A., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.06.005 · Cited by 13
Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients
Zhang, Y., Shi, Y., Wu, R., Wang, X., Gao, X., & Niu, J. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001100 · Cited by 13
Bateson, M. C., & Gedling, P. (1998) · Postgraduate Medical Journal · doi:10.1136/pgmj.74.874.482 · Cited by 13
Clinical features and prognosis of primary biliary cirrhosis in Korea
Kim, K., Jeong, S., Lee, J. I., Yeon, J. E., Lee, H. J., Kwon, S. Y., Chang, U. I., & Min, H. J. (2010) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2010.16.2.139 · Cited by 12
Proposed therapies in primary biliary cholangitis
Floreani, A., Sun, Y. H., Zou, Z. S., Li, B., Cazzagon, N., Bowlus, C. L., & Gershwin, M. E. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1121810 · Cited by 14
Identification of clinical risk factors for histological progression of primary biliary cholangitis
Fujinaga, Y., Namisaki, T., Moriya, K., Kitade, M., Kawaratani, H., Shimozato, N., Kaji, K., Takaya, H., Sawada, Y., Seki, K., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13355 · Cited by 13
Effect of genipin on the biliary excretion of cholephilic compounds in rats
Mikami, M., & Takikawa, H. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00309.x · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Self-citationYu, S., Vidal, B., Peric, M., Rosenbaum, M. W., Cates, J., & González, R. S. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.03.003 · Cited by 12
Current Treatment Options for Primary Biliary Cholangitis
Wong, K. A., Bahar, R., Liu, C. H., & Bowlus, C. L. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.003 · Cited by 11
Namisaki, T., Fujinaga, Y., Moriya, K., & Yoshiji, H. (2021) · Hepatology Research · doi:10.1111/hepr.13593 · Cited by 12
Gao, Y., Li, L., Li, B., & Zhan, Y. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8829510 · Cited by 11
“Primary biliary cholangitis (PBC, also known as primary biliary cirrhosis) is a chronic progressive autoimmune liver disease that causes ductopenia, cholestasis, and fibrosis [1–3].”
Li, Z., Liu, Y., Li, X., Wu, Y., Yang, F., Mo, Q.-W., & Chong, Y. (2020) · BioMed Research International · doi:10.1155/2020/5162541 · Cited by 12
Goto, H., & Takikawa, H. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00630.x · Cited by 10
PREDICTIVE MODELS OF NATURAL HISTORY IN PRIMARY BILIARY CIRRHOSIS
Kim, W. R., & Dickson, E. R. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70010-6 · Cited by 10
Self-citationTreatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Primary biliary cholangitis: review for radiologists
Morgan, M. A., & Sundaram, K. M. (2021) · Abdominal Radiology · doi:10.1007/s00261-021-03335-x · Cited by 9
Kang, J., & Lee, M. (2017) · InTech eBooks · doi:10.5772/intechopen.68317 · Cited by 11
“In primary biliary cirrhosis (PBC), sequential liver biopsies may assist one to investigate the natural history, track the responses of therapy, or identify a recurrence of the disease after liver transplantation [66, 67].”
BackgroundInvestigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis
Akepati, P. R., & Gochanour, E. M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2348743 · Cited by 8
“Untreated liver injury in PBC progresses through various stages of fibrosis and may eventually result in cirrhosis, although the rate of this progression varies in individual patients [34].”
BackgroundLindor, K. D., & Levy, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00041-3 · Cited by 9
Self-citationJayabalan, D., Huang, Y., Bertot, L. C., Adams, L. A., Cheng, W., Hazeldine, S., Smith, B. W., MacQuillan, G. C., Wallace, M. C., Garas, G., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16850 · Cited by 8
Novel Therapies in Primary Biliary Cholangitis
Buchanan-Peart, K.-A., & Levy, C. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.013 · Cited by 7
Review: Current status of therapy in autoimmune liver disease
Hirschfield, G. M., Al‐Harthy, N., & Heathcote, E. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08098966 · Cited by 7
Longerich, T., Flechtenmacher, C., & Schirmacher, P. (2008) · Der Pathologe · doi:10.1007/s00292-007-0963-1 · Cited by 11
Trials in primary biliary cirrhosis: Need for the right drugs at the right time†
Poupon, R. Y. (2004) · Hepatology · doi:10.1002/hep.20188 · Cited by 8
Gulamhusein, A. F., & Hansen, B. E. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.12.008 · Cited by 7
Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
Cumpian, N. A., Choi, G., & Saab, S. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08742-w · Cited by 6
“After 4 years without treatment, 50% of affected patients were diagnosed with cirrhosis despite an initial presentation of hepatitis without fibrosis [5].”
Ishibashi, H., Nakanuma, Y., Ueno, Y., Egawa, H., Koike, K., Komori, A., Sakisaka, S., Shimoda, S., Shirabe, K., Zeniya, M., et al. (2012) · Kanzo · doi:10.2957/kanzo.53.633 · Cited by 7
Zhu, J., Shi, Y., Zhou, X., Li, Z., Huang, X., Han, Z., Wang, J., Wang, R., Ding, J., Wu, K., et al. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0227-1 · Cited by 6
“Majority of patients with PBC will progress histologically within 2 years [30].”
BackgroundPrimary Biliary Cholangitis: A Review
Xu, H. Z., & Yanny, B. (2022) · Gene Expression · doi:10.14218/gejlr.2022.00013 · Cited by 7
Aishima, S., KURODA, Y., Nishihara, Y., TAGUCHI, K., Yoshizumi, T., Taketomi, A., Maehara, Y., & Tsuneyoshi, M. (2006) · Hepatology Research · doi:10.1016/j.hepres.2006.07.008 · Cited by 6
Vierling, J. M. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70085-4 · Cited by 6
Historia natural de la cirrosis biliar primaria
Parés, A. R. (2008) · Gastroenterología y Hepatología · doi:10.1157/13127093 · Cited by 10
Gerussi, A., & Carbone, M. (2020) · Wiley eBooks · doi:10.1002/9781119532637.ch7 · Cited by 5
Selmi, C. F., & Gershwin, M. E. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-285-8_55 · Cited by 5
PBC: Animal Models of Cholangiopathies and Possible Endogenous Viral Infections
Ninomiya, M., Ueno, Y., & Shimosegawa, T. (2011) · International Journal of Hepatology · doi:10.1155/2012/649290 · Cited by 4
“In human PBC, the destruction of cholangiocytes leads to ductpenia [48].”
BackgroundOxides, Onions, and Other Matters Gastrointestinal-1996-A Perspective
Kapadia, C. R. (1997) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199704000-00003 · Cited by 4
Chatzipantelis, P., & Giatromanolaki, A. N. (2021) · PubMed · doi:10.1097/meg.0000000000001876 · Cited by 3
Sarcoidosis with hepatic involvement in a 60-year-old patient
Houten, L. V., Horst, M., & Samii, S. (2022) · Journal of Radiology Case Reports · doi:10.3941/jrcr.v16i3.4191 · Cited by 3
Bayesian inference for Cox regression models using catalytic prior distributions
Li, W., & Huang, D. (2026) · Biometrics · doi:10.1093/biomtc/ujag004 · Cited by 3
Acharya, S., Shrestha, S., Poddar, E., Neupane, A., Khadayat, R., Magar, S. R., Lamsal, M., & Pathak, R. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001143 · Cited by 3
“Within 4 years, progression towards cirrhosis was observed in 40% of patients with an early histological disease stage (stage I or II) and in 68% of patients with advanced disease (stage III) [25] .”
BackgroundSchuppan, D., & Hahn, E. G. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_8 · Cited by 3
UDCA, PBC and biochemistry: what does normal mean?
Lindor, K. D. (2000) · Gut · doi:10.1136/gut.46.1.8 · Cited by 3
Self-citationDesmet, V. J., & Rosaí, J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06969-4.00001-5 · Cited by 4
Bowlus, C. L., Nevens, F., Kowdley, K. V., Bonder, A., Capozza, T. A., Li, J., Nair, R., Trauner, M., & Jones, D. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70832 · Cited by 2
Sclair, S. N., & Levy, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00042-2 · Cited by 3
Chen, X., Ma, X., Wang, R., Wang, L., Li, J., Liu, H., He, T., Wei, S., Li, H., Wang, M., et al. (2020) · Medicine · doi:10.1097/md.0000000000023107 · Cited by 2
Levy, C., Carrion, A. F., & Mayo, M. J. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch21 · Cited by 2
Chen, P.-T., & Chen, H. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.05.020 · Cited by 2
Investigating the therapeutic potential of low-level laser therapy in mitigating liver fibrosis
Mohamed, A. E., Mahmoud, A. M., Mohamed, W. R., & Mohamed, T. A. (2024) · Laser Innovations for Research and Applications. · doi:10.21608/lira.2024.357511 · Cited by 1
Primary biliary cholangitis, a rising health burden
Elnaggar, M., Elkhattib, I., Abomhya, A., & Boyer, J. L. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00165 · Cited by 1
A Rare Case of Concurrent Primary Biliary Cholangitis and Sarcoidosis
Gordon, R. S., Bandaru, M., Yaratha, L., Borum, M. L., & Younes, M. (2025) · Cureus · doi:10.7759/cureus.80228 · Cited by 1
Indications for Liver Transplantation
Cucchetti, A., Vukotic, R., Andreoné, P., Piscaglia, F., Pecorelli, A., Bolondi, L., Morelli, M. C., Ercolani, G., Cescon, M., Ravaioli, M., et al. (2015) · Springer eBooks · doi:10.1007/978-3-319-16997-2_6 · Cited by 1
“A meta-analysis of randomized placebo-controlled studies of UDCA concluded that about 20 % of patients treated with UDCA will have no histological progression over 4 years, and some will have no progression over a decade or longer [ 83 ].”
MethodPrimary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis)
Trivedi, P. J., & Hirschfield, G. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch38 · Cited by 1
Rigopoulou, E. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-24432-3_24 · Cited by 1
Trivella, J. P., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00018-3 · Cited by 1
Examining the increased IgM production and ursodeoxycholic acid treatment in PBC
Lazaridis, K. N., & LaRusso, N. F. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.040 · Cited by 1
NON INVASIVE EVALUATION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B AND C
Ashraf, S. (2009) · HEC National Digital Library · Cited by 1
Protocolo diagn?stico de la enfermedad hep?tica autoinmune
Chaparro, M., Moreno-Monteagudo, J. A., Garca-Buey, L. C., & Moreno‐Otero, R. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73158-8 · Cited by 1
Strassburg, C. P., Lüttig, B., & Manns, M. P. (2000) · Springer eBooks · doi:10.1007/978-3-642-57194-7_49 · Cited by 1
Woolliscroft, J. O. (2001) · doi:10.1007/978-1-4684-0614-6_4 · Cited by 1
Dancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_19
Epidemiology and Treatment Options of Primary Biliary Cirrhosis
Rautiainen, H. (2008) · Helda - University of Helsinki Institutional Repository
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Corpechot, C. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.870031
“It has been estimated from a historical cohort in the 1970s that the 4-year incidence of cirrhosis was 30, 50 and 68% at histological stages I, II and III, respectively [83].”
BackgroundThe Evolutionary Pattern of Primary Sclerosing Cholangitis: From a Benign to Severe Disease
D'Innocenzo, S., Russo, F., Miglioresi, L., Bacosi, M., & Ricci, G. (2002) · Springer eBooks · doi:10.1007/978-94-017-0637-7_5
Schuppan, D., & Hahn, E. G. (1998)
Autoimmune Liver Diseases: Primary Biliary Cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_16
Self-citationCarey, E. J., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/s1089-3261(18)30044-8 · Cited by 1
Júnior, A., Menezes, L. V. P., Fahham, L., Fernandes, R. Z. S., & Teich, V. (2018) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v10.n1.p45-55
Cirrhosis and Autoimmune Liver Disease
Stirnimann, G., Ebadi, M., Mason, A. L., & Montaño‐Loza, A. J. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00449-1
Liver Cirrhosis with Autoimmune Liver Diseases: AIH and PBC
Abe, K., Takahashi, A., & Ohira, H. (2019) · Springer eBooks · doi:10.1007/978-981-13-7979-6_2
Diseases of the Liver: Primary Biliary Cholangitis
Phillips, P. K., & Said, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-25626-5_7
Transplant and Autoimmune Diseases
Gambato, M., & Russo, F. P. (2021) · Springer eBooks · doi:10.1007/978-3-030-65908-0_16
Do we still need liver biopsies?
Flechtenmacher, C., Longerich, T., & Schirmacher, P. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8767-7_13
Albhaisi, S. A. M., & Sanyal, A. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65720-3
Fibrosis induced by chronic cholestatic diseases
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00005-6
Mandel, L. (2024) · Springer eBooks · doi:10.1007/978-3-031-50012-1_7
Histologische Diagnostik von Fibrose und Zirrhose
Longerich, T. (2025) · Springer eBooks · doi:10.1007/978-3-662-70167-6_5
Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States
Kumar, S., Shamseddine, N., Yang, H., Zhang, S., Ye, D., Seshasayee, S. M., Chen, J., & Kowdley, K. V. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03439-6
Histopathological Scoring Systems
Longerich, T., & Schirmacher, P. (2009) · Springer eBooks · doi:10.1007/978-3-540-93842-2_29
“Scheuer’s score) has prognostic relevance since stage regression is infrequent [ 46 ].”
BackgroundFan, Z., Jia, S., Wei, Y., Fan, X., Li, X., & Wang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845113
“Historical studies have suggested that untreated patients with PBC have a substantially increased risk of hepatic decompensation (53).”
Shamseddine, N., Yang, H., Zhang, S., Ye, D., Seshasayee, S. M., Chen, J., Kumar, S. R., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0172
van der Meer, A. J., & Trivedi, P. J. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch20
Metadata
- Authors
- Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Hepatology
- Published
- 1996-01
- Volume
- 23
- Issue
- 1
- Pages
- 52-56
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2112332162
- Cited by
- 184
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 9 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 5
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 7183 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 34-238-07A1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- primary biliary cirrhosis, histological progression, histological staging, liver biopsy, D-penicillamine, Markov model, disease progression rate, histological regression, clinical trial design, treatment efficacy assessment
- MeSH terms
- Biopsy, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Biliary, Male, Markov Chains, Middle Aged, Penicillamine, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.